🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New #JITC article: Nanoparticles targeting immune checkpoint protein VISTA induce potent antitumor immunity bit.ly/3X7SaH6

New #JITC article: Neutralizing IL-38 activates γδ T cell-dependent antitumor immunity and sensitizes for chemotherapy bit.ly/3yZ736E Javier Garcia-Pardo

New #JITC article: Identification of Siglec-10 as a new dendritic cell checkpoint for cervical cancer immunotherapy bit.ly/3WXCB4E

August Society for Immunotherapy of Cancer #JITC Reading List by Deputy Editor-in-Chief Sjoerd van der Burg LUMC Leiden selection #4: Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction by Whitehead Institute Dana-Farber Harvard Medical School Koch Institute at MIT bit.ly/4dV6KZz

New #JITC article: Adenovirus vaccine targeting kinases induces potent antitumor immunity in solid tumors bit.ly/4e0tyHh

New #JITC commentary: Immune checkpoint blockade: timing is everything bit.ly/4e3UpC8 Frank Sinicrope, MD

New #JITC article: Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab bit.ly/3MrU0O4 Tammy Sussman MD Annie Silk Riz Haq MD PhD elizabeth buchbinder

New #JITC article: Tumor microenvironment biomarkers predicting pathological response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma: post-hoc analysis of a single center, phase 2 study bit.ly/3Moo511

New #JITC review: Inclusion, characteristics, and reporting of older adults in FDA registration studies of immunotherapy, 2018–2022 bit.ly/3AWqiy8 Colm Mac Eochagain Dr Mukul Roy Nicolò Battisti, MD

New #JITC article: NKG2C/KLRC2 tumor cell expression enhances immunotherapeutic efficacy against glioblastoma bit.ly/479GUPc Pilar Sánchez-Gomez

Now through September 19, we are collecting mentee applications for our third year of the #JITC Peer Review Mentorship Program! Apply today: bit.ly/3cse6sM Society for Immunotherapy of Cancer SITC Early Career Scientist Committee

New #JITC review: Immune modulatory microRNAs in tumors, their clinical relevance in diagnosis and therapy bit.ly/3Z5iOmM

New #JITC article: Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment

Very proud and excited to share this collaborative work published in #JITC, where we describe how IL-38 neutralization with engineered antibodies activates γδ T cell-dependent antitumor immunity and enhances sensitivity to chemotherapy. 👉bit.ly/3yZ736E.

New #JITC Article: Non-invasive multimodal CT deep learning biomarker to predict pathological complete response of non-small cell lung cancer following neoadjuvant immunochemotherapy: a multicenter study bit.ly/4cYCsE6

Ne #JITC Article: Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy bit.ly/3ZeL5Hw

"This program provides an excellent training opportunity and I feel I have a good foundation for reviewing papers on my own now." - 2024 Class Mentee This could be you, too! Apply for your spot in the 2025 #JITC Peer Review Mentorship Program today: bit.ly/3cse6sM

New #JITC article: Loss of Annexin A1 in macrophages restrains efferocytosis and remodels immune microenvironment in pancreatic cancer by activating the cGAS/STING pathway bit.ly/3MAjzgc

New #JITC commentary: scRNA+ TCR-seq revealed dual TCR T cells antitumor response in the TME of NSCLC bit.ly/4cSZ9tn

New #JITC article: Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma bit.ly/3yWwxSk Vernon K Sondak MD Nikhil Khushalani Andrew Brohl